Background: Triweekly high-dose cisplatin (100 mg/m ) with concurrent radiation therapy is the current standard of care in the definitive or appropriate postoperative setting in head and neck squamous cell carcinoma (HNSCC). We compared triweekly 100 mg/m with alternative weekly 40 mg/m and weekly <40 mg/m cisplatin regimens.
Methods: From 2011 to 2016, 163 patients received concurrent cisplatin and intensity-modulated radiotherapy for locally advanced HNSCC. Primary endpoints were overall survival (OS) and progression-free survival.
Results: Cisplatin weekly <40 mg/m showed inferior OS outcomes when compared to weekly 40 mg/m (P = 0.084) and triweekly 100 mg/m (P = 0.04) regimens.
Conclusion: Our study displayed inferior outcomes with weekly cisplatin doses under 40 mg/m , suggesting the inferiority of low-dose weekly chemotherapy and the need for ongoing randomized trials to further explore 40 vs 100 mg/m chemotherapy regimens.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/hed.25717 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Screening and identification of vascular endothelial cell targeting peptide in gastric cancer through novel integrated in vitro and in vivo strategy.
BMC Cancer
December 2024
Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou, 510515, Guangdong, P.R. China.
Purpose: Antiangiogenesis therapy has become a hot field in cancer research. Given that tumor blood vessels often express specific markers related to angiogenesis, the study of these heterogeneous molecules in different tumor vessels holds promise for advancing anti-angiogenic therapy. Previously using phage display technology, we identified a targeting peptide named GX1 homing to gastric cancer vessels for the first time.
View Article and Find Full Text PDFImmunochemotherapy plus radiotherapy versus immunochemotherapy alone as first-line treatment for treatment-naïve, advanced esophageal squamous cell carcinoma (AEC-ICR-1st): A multi-center cohort study.
Cancer Lett
December 2024
Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China. Electronic address:
Immunochemotherapy is Currently the standard first-line treatment for advanced esophageal squamous cell carcinoma (ESCC). However, its prognosis remains unsatisfactory. We aimed to evaluate the efficacy and safety of immunochemotherapy plus radiotherapy (ICR) compared with immunochemotherapy (IC) alone as a first-line treatment for advanced ESCC.
View Article and Find Full Text PDFAbscopal Effect in a Patient With Metastatic Melanoma Receiving Hypofractionated Radiation Therapy and Dual Immune Checkpoint Inhibition: A Case Report.
Cureus
November 2024
Radiation Oncology, Fox Chase Cancer Center, Temple University Hospital, Philadelphia, USA.
Concurrent with the increasing utilization of immune checkpoint inhibitors (ICIs) in melanoma, there has been renewed interest in understanding the potential interplay between radiation therapy (RT) and the immune system. One such phenomenon is the abscopal effect, where localized treatments, such as RT, not only shrink the targeted tumor but also induce shrinkage of untreated tumors elsewhere in the body. Here, we report a case of an abscopal effect in a 63-year-old patient with metastatic melanoma who was progressing on first-line dual ICI therapy but experienced a rapid and durable systemic response following the administration of hypofractionated palliative RT to a large primary melanoma skin tumor.
View Article and Find Full Text PDFA simplified scoring system for predicting treatment response in limited-stage small-cell lung cancer (EAST score).
Future Oncol
December 2024
Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Aims: This study aimed at developing a scoring system (EAST score) to predict recurrence after chemoradiotherapy in limited-stage small-cell lung cancer (LS-SCLC).
Patients & Methods: Treatment-naïve LS-SCLC patients receiving concurrent chemoradiotherapy (CCRT) ( = 234) or sequential chemoradiotherapy ( = 53) were retrospectively reviewed. Using data from CCRT population, clinical and radiological variables associated with disease progression were identified.
Prognostic value of pseudotime from texture parameters of FDG PET/CT in locally advanced rectal cancer with neoadjuvant concurrent chemoradiotherapy.
Sci Rep
December 2024
Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro, Gangnam-Gu, Seoul, 06351, Republic of Korea.
Texture analysis generates image parameters from F-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT). Although some parameters correlate with tumor biology and clinical attributes, their types and implications can be complex. To overcome this limitation, pseudotime analysis was applied to texture parameters to estimate changes in individual sample characteristics, and the prognostic significance of the estimated pseudotime of primary tumors was evaluated.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!